ESMO: AstraZeneca faces challenge with FDA as Imfinzi, Lynparza miss survival goal in ovarian cancer
More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback